Conor Medsystems Inc. v Angiotech Pharmaceuticals Inc. and another
| Jurisdiction | England & Wales |
| Date | 2009 |
| Year | 2009 |
| Court | House of Lords |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
4 cases
-
Glaxosmithkline UK Ltd v Wyeth Holdings Llc
...iv) "Plausibility" is also relevant to AgrEvo-type obviousness, as explained in the cases reviewed by Lord Hoffmann in Conor Medsystems Inc v Angiotech Pharmaceuticals Inc [2008] RPC 8 at [31]–[35], and it is the same threshold test. In particular, Lord Hoffmann stated at [37] that there wa......
-
Medimmune Ltd v Novartis Pharmaceuticals UK Ltd
...court to seek to resolve their disagreement, for ultimately all that matters is what the patentee has claimed. As Lord Hoffmann said in Conor v Angiotech [2008] UKHL 49, [2008] RPC 716 at [19]: "… the patentee is entitled to have the question of obviousness determined by reference to the cl......
-
Accord Healthcare Ltd v Medac Gesellschaft Für Klinische Spezialpräparate MBH
...as Kitchin J (as he was then) put it in the much cited passage from Generics v Lundbeck [2007] RPC 32 at paragraph 72, approved in Conor v Angiotech [2008] UKHL 49. 62 In Medimmune Kitchin LJ explained that in cases involving a question of whether something is "obvious to try", that is only......
-
Glenmark Generics (Europe) Ltd Generics [UK] Ltd (T/A Mylan) v The Wellcome Foundation Ltd Glaxo Group Ltd (Defendants/Part 20 Claimants)
... ... to a placebo or by comparison with another drug ... 55 ... to common general knowledge in KCI Licensing Inc v Smith & Nephew plc [2010] EWHC 1487 (Pat), ... , in MedImmune Ltd v Novartis Pharmaceuticals Ltd [2012] EWCA Civ 1234 as follows: ... summarised the position in this way in Conor at [42]: 'In the Court of ... ...